Brief: Nanexa To Resume Phase I Study With Nex-22 With Further Dose Escalation
28/01/2025 07:32
Jan 28 (Reuters) - Nanexa AB NANEXA.ST :
* PHASE I STUDY WITH NEX-22 TO RESUME WITH FURTHER DOSE
ESCALATION
WITH ESTIMATED START IN THE FIRST QUARTER OF 2025
Source text: ID:nMFNcgSjTs
Further company coverage: NANEXA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))